Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Factors in the emergence of serious human infections associated with highly pathogenic strains of shiga toxin-producing Escherichia coli.

Karmali MA.

Int J Med Microbiol. 2018 Dec;308(8):1067-1072. doi: 10.1016/j.ijmm.2018.08.005. Epub 2018 Aug 19. Review.

PMID:
30146439
2.

Emerging Public Health Challenges of Shiga Toxin-Producing Escherichia coli Related to Changes in the Pathogen, the Population, and the Environment.

Karmali MA.

Clin Infect Dis. 2017 Feb 1;64(3):371-376. doi: 10.1093/cid/ciw708. Epub 2016 Oct 21. Review.

PMID:
27986670
3.

Vector-borne diseases, climate change and healthy urban living: Next steps.

Mathieu K, Karmali M.

Can Commun Dis Rep. 2016 Oct 6;42(10):219-221. eCollection 2016 Oct 6. No abstract available.

4.

Introduction to emerging vector-borne disease and cities workshop proceedings.

Karmali M, Weinstock D.

Can Commun Dis Rep. 2016 Oct 6;42(10):197. eCollection 2016 Oct 6. No abstract available.

5.

Plasma 25-hydroxyvitamin D, hormonal contraceptive use, and cardiometabolic disease risk in an ethnically diverse population of young adults.

García-Bailo B, Karmali M, Badawi A, El-Sohemy A.

J Am Coll Nutr. 2013;32(5):296-306. doi: 10.1080/07315724.2013.826112.

PMID:
24219372
6.

Plasma vitamin D and biomarkers of cardiometabolic disease risk in adult Canadians, 2007-2009.

García-Bailo B, Da Costa LA, Arora P, Karmali M, El-Sohemy A, Badawi A.

Prev Chronic Dis. 2013 Jun 6;10:E91. doi: 10.5888/pcd10.120230.

7.

Common variants of the vitamin D binding protein gene and adverse health outcomes.

Malik S, Fu L, Juras DJ, Karmali M, Wong BY, Gozdzik A, Cole DE.

Crit Rev Clin Lab Sci. 2013 Jan-Feb;50(1):1-22. doi: 10.3109/10408363.2012.750262. Epub 2013 Feb 22. Review.

8.

The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults.

Da Costa LA, Arora P, García-Bailo B, Karmali M, El-Sohemy A, Badawi A.

Diabetes Metab Syndr Obes. 2012;5:347-55. doi: 10.2147/DMSO.S35115. Epub 2012 Oct 4.

9.

Novel repressor of Escherichia coli O157:H7 motility encoded in the putative fimbrial cluster OI-1.

Allison SE, Silphaduang U, Mascarenhas M, Konczy P, Quan Q, Karmali M, Coombes BK.

J Bacteriol. 2012 Oct;194(19):5343-52. doi: 10.1128/JB.01025-12. Epub 2012 Jul 27.

10.

Effects of polymorphisms in nucleotide-binding oligomerization domains 1 and 2 on biomarkers of the metabolic syndrome and type II diabetes.

Cuda C, Badawi A, Karmali M, El-Sohemy A.

Genes Nutr. 2012 Jul;7(3):427-35. doi: 10.1007/s12263-012-0287-5. Epub 2012 Feb 26.

11.

A common polymorphism near the interleukin-6 gene modifies the association between dietary fat intake and insulin sensitivity.

Cuda C, Garcia-Bailo B, Karmali M, El-Sohemy A, Badawi A.

J Inflamm Res. 2012;5:1-6. doi: 10.2147/JIR.S27911. Epub 2012 Jan 9.

12.

Dietary patterns and ethnicity are associated with distinct plasma proteomic groups.

García-Bailo B, Brenner DR, Nielsen D, Lee HJ, Domanski D, Kuzyk M, Borchers CH, Badawi A, Karmali MA, El-Sohemy A.

Am J Clin Nutr. 2012 Feb;95(2):352-61. doi: 10.3945/ajcn.111.022657. Epub 2011 Dec 28.

PMID:
22205312
13.

Plasma vitamin D levels and risk of metabolic syndrome in Canadians.

Brenner DR, Arora P, Garcia-Bailo B, Wolever TM, Morrison H, El-Sohemy A, Karmali M, Badawi A.

Clin Invest Med. 2011 Dec 1;34(6):E377.

PMID:
22129928
14.

Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes.

Arora P, Garcia-Bailo B, Dastani Z, Brenner D, Villegas A, Malik S, Spector TD, Richards B, El-Sohemy A, Karmali M, Badawi A.

BMC Med Genet. 2011 Jul 14;12:95. doi: 10.1186/1471-2350-12-95.

15.

Rapid genoserotyping tool for classification of Salmonella serovars.

Franklin K, Lingohr EJ, Yoshida C, Anjum M, Bodrossy L, Clark CG, Kropinski AM, Karmali MA.

J Clin Microbiol. 2011 Aug;49(8):2954-65. doi: 10.1128/JCM.02347-10. Epub 2011 Jun 22.

16.

Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease.

Sepehri S, Khafipour E, Bernstein CN, Coombes BK, Pilar AV, Karmali M, Ziebell K, Krause DO.

Inflamm Bowel Dis. 2011 Jul;17(7):1451-63. doi: 10.1002/ibd.21509. Epub 2010 Dec 9.

PMID:
21674703
17.

Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans.

Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA.

Clin Vaccine Immunol. 2011 Jul;18(7):1052-7. doi: 10.1128/CVI.00068-11. Epub 2011 May 18.

18.

Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress.

Garcia-Bailo B, El-Sohemy A, Haddad PS, Arora P, Benzaied F, Karmali M, Badawi A.

Biologics. 2011;5:7-19. doi: 10.2147/BTT.S14417. Epub 2011 Jan 19.

19.

Polymorphisms in Toll-like receptor 4 are associated with factors of the metabolic syndrome and modify the association between dietary saturated fat and fasting high-density lipoprotein cholesterol.

Cuda C, Badawi A, Karmali M, El-Sohemy A.

Metabolism. 2011 Aug;60(8):1131-5. doi: 10.1016/j.metabol.2010.12.006. Epub 2011 Feb 8.

PMID:
21306745
20.

Extending the reach of public health genomics: what should be the agenda for public health in an era of genome-based and “personalized” medicine?

Burke W, Burton H, Hall AE, Karmali M, Khoury MJ, Knoppers B, Meslin EM, Stanley F, Wright CF, Zimmern RL; Ickworth Group.

Genet Med. 2010 Dec;12(12):785-91. doi: 10.1097/GIM.0b013e3182011222.

PMID:
21189494
21.

Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypes.

Nash JH, Villegas A, Kropinski AM, Aguilar-Valenzuela R, Konczy P, Mascarenhas M, Ziebell K, Torres AG, Karmali MA, Coombes BK.

BMC Genomics. 2010 Nov 25;11:667. doi: 10.1186/1471-2164-11-667.

22.

Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention.

Badawi A, Klip A, Haddad P, Cole DE, Bailo BG, El-Sohemy A, Karmali M.

Diabetes Metab Syndr Obes. 2010 May 26;3:173-86.

23.

Lineage and host source are both correlated with levels of Shiga toxin 2 production by Escherichia coli O157:H7 strains.

Zhang Y, Laing C, Zhang Z, Hallewell J, You C, Ziebell K, Johnson RP, Kropinski AM, Thomas JE, Karmali M, Gannon VP.

Appl Environ Microbiol. 2010 Jan;76(2):474-82. doi: 10.1128/AEM.01288-09. Epub 2009 Nov 30.

24.

In silico genomic analyses reveal three distinct lineages of Escherichia coli O157:H7, one of which is associated with hyper-virulence.

Laing CR, Buchanan C, Taboada EN, Zhang Y, Karmali MA, Thomas JE, Gannon VP.

BMC Genomics. 2009 Jun 29;10:287. doi: 10.1186/1471-2164-10-287.

25.

Verocytotoxin-producing Escherichia coli (VTEC).

Karmali MA, Gannon V, Sargeant JM.

Vet Microbiol. 2010 Jan 27;140(3-4):360-70. doi: 10.1016/j.vetmic.2009.04.011. Epub 2009 Apr 10. Review.

PMID:
19410388
26.

Enterohemorrhagic Escherichia coli O157:H7 gene expression profiling in response to growth in the presence of host epithelia.

Jandu N, Ho NK, Donato KA, Karmali MA, Mascarenhas M, Duffy SP, Tailor C, Sherman PM.

PLoS One. 2009;4(3):e4889. doi: 10.1371/journal.pone.0004889. Epub 2009 Mar 18.

27.

Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Karmali MA.

Kidney Int Suppl. 2009 Feb;(112):S4-7. doi: 10.1038/ki.2008.608. Review.

28.

Genomic O island 122, locus for enterocyte effacement, and the evolution of virulent verocytotoxin-producing Escherichia coli.

Konczy P, Ziebell K, Mascarenhas M, Choi A, Michaud C, Kropinski AM, Whittam TS, Wickham M, Finlay B, Karmali MA.

J Bacteriol. 2008 Sep;190(17):5832-40. doi: 10.1128/JB.00480-08. Epub 2008 Jun 27.

29.

The continuing evolution of a bacterial pathogen.

Kaper JB, Karmali MA.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4535-6. doi: 10.1073/pnas.0801435105. Epub 2008 Mar 19. No abstract available.

30.

Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains.

Coombes BK, Wickham ME, Mascarenhas M, Gruenheid S, Finlay BB, Karmali MA.

Appl Environ Microbiol. 2008 Apr;74(7):2153-60. doi: 10.1128/AEM.02566-07. Epub 2008 Feb 1.

31.

Applicability of phylogenetic methods for characterizing the public health significance of verocytotoxin-producing Escherichia coli strains.

Ziebell K, Konczy P, Yong I, Frost S, Mascarenhas M, Kropinski AM, Whittam TS, Read SC, Karmali MA.

Appl Environ Microbiol. 2008 Mar;74(5):1671-5. doi: 10.1128/AEM.01619-07. Epub 2007 Dec 28.

32.

Isolation and genetic characterization of a coinfection of non-O157 Shiga toxin-producing Escherichia coli.

Gilmour MW, Tabor H, Wang G, Clark CG, Tracz DM, Olson AB, Mascarenhas M, Karmali MA, Mailman T, Ng LK.

J Clin Microbiol. 2007 Nov;45(11):3771-3. Epub 2007 Sep 5.

33.

Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleE.

Wickham ME, Lupp C, Vázquez A, Mascarenhas M, Coburn B, Coombes BK, Karmali MA, Puente JL, Deng W, Finlay BB.

Microbes Infect. 2007 Mar;9(3):400-7. Epub 2007 Jan 13.

PMID:
17317262
34.

Repression of intracellular virulence factors in Salmonella by the Hha and YdgT nucleoid-associated proteins.

Silphaduang U, Mascarenhas M, Karmali M, Coombes BK.

J Bacteriol. 2007 May;189(9):3669-73. Epub 2007 Feb 16.

35.

Multiple seropathotypes of verotoxin-producing Escherichia coli (VTEC) disrupt interferon-gamma-induced tyrosine phosphorylation of signal transducer and activator of transcription (Stat)-1.

Jandu N, Shen S, Wickham ME, Prajapati R, Finlay BB, Karmali MA, Sherman PM.

Microb Pathog. 2007 Feb-Mar;42(2-3):62-71. Epub 2006 Dec 15.

PMID:
17174521
36.

Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells.

Te Loo DM, Monnens L, van der Velden T, Karmali M, van den Heuvel L, van Hinsbergh V.

Pediatr Nephrol. 2006 Dec;21(12):1815-23. Epub 2006 Aug 30.

PMID:
16944213
37.

Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection.

Wickham ME, Lupp C, Mascarenhas M, Vazquez A, Coombes BK, Brown NF, Coburn BA, Deng W, Puente JL, Karmali MA, Finlay BB.

J Infect Dis. 2006 Sep 15;194(6):819-27. Epub 2006 Aug 11.

PMID:
16941350
38.

Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function.

Zareie M, Riff J, Donato K, McKay DM, Perdue MH, Soderholm JD, Karmali M, Cohen MB, Hawkins J, Sherman PM.

Cell Microbiol. 2005 Dec;7(12):1782-97.

PMID:
16309464
39.
40.
41.

SepZ/EspZ is secreted and translocated into HeLa cells by the enteropathogenic Escherichia coli type III secretion system.

Kanack KJ, Crawford JA, Tatsuno I, Karmali MA, Kaper JB.

Infect Immun. 2005 Jul;73(7):4327-37.

42.

The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. 1985.

Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H.

J Infect Dis. 2004 Feb 1;189(3):556-63. No abstract available.

PMID:
14982069
43.

Evidence for a hybrid genomic island in verocytotoxin-producing Escherichia coli CL3 (serotype O113:H21) containing segments of EDL933 (serotype O157:H7) O islands 122 and 48.

Shen S, Mascarenhas M, Rahn K, Kaper JB, Karmali MA.

Infect Immun. 2004 Mar;72(3):1496-503. Erratum in: Infect Immun. 2004 Jul;72(7):4330. Karmal MA [corrected to Karmali MA].

44.

Infection by Shiga toxin-producing Escherichia coli: an overview.

Karmali MA.

Mol Biotechnol. 2004 Feb;26(2):117-22. Review.

PMID:
14764937
45.
46.

Age-specific frequencies of antibodies to Escherichia coli verocytotoxins (Shiga toxins) 1 and 2 among urban and rural populations in southern Ontario.

Karmali MA, Mascarenhas M, Petric M, Dutil L, Rahn K, Ludwig K, Arbus GS, Michel P, Sherman PM, Wilson J, Johnson R, Kaper JB.

J Infect Dis. 2003 Dec 1;188(11):1724-9. Epub 2003 Nov 14.

PMID:
14639544
47.

Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease.

Karmali MA, Mascarenhas M, Shen S, Ziebell K, Johnson S, Reid-Smith R, Isaac-Renton J, Clark C, Rahn K, Kaper JB.

J Clin Microbiol. 2003 Nov;41(11):4930-40.

48.

The medical significance of Shiga toxin-producing Escherichia coli infections. An overview.

Karmali MA.

Methods Mol Med. 2003;73:1-7. Review. No abstract available.

PMID:
12375423
49.
50.

Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.

Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, Ruder H, Laufs R, Sobottka I, Petric M, Karch H, Müller-Wiefel DE.

J Clin Microbiol. 2002 May;40(5):1773-82.

Supplemental Content

Loading ...
Support Center